Scipher Medicine to Participate in Truist Securities Life Sciences AI Symposium

WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced Chief Technology Officer Slava Akmaev, Ph.D., will participate in a virtual panel at the Truist Securities Life Sciences AI Symposium on Tuesday, March 1, 2022, at 10:10 a.m. ET.

About Scipher Medicine

Scipher Medicine, a precision immunology company matching patients with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, our proprietary network medicine platform, we commercialize tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, health care providers, and pharmaceutical companies to bring solutions to patients with autoimmune diseases. Visit http://www.sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

Contacts

Media Contact
Molly Johnson

Director, Corporate Communications

PR@scipher.com
216-410-5218

Investor Contact
John Strumbos, Ph.D., MBA

Chief Financial Officer

IR@scipher.com